AI assistant
Oramed Pharmaceuticals Inc. — Director's Dealing 2024
Jan 8, 2024
6965_dirs_2024-01-08_8269b003-2bbd-4cfc-82a2-949dfc2350bf.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: ORAMED PHARMACEUTICALS INC. (ORMP)
CIK: 0001176309
Period of Report: 2024-01-04
Reporting Person: Shapiro Benjamin (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-01-04 | Common Stock | A | 30000 | — | Acquired | 50000 | Direct |
| 2024-01-04 | Common Stock | A | 5070 | — | Acquired | 55070 | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 1900000 | Indirect |
Footnotes
F1: Represents Restricted Stock Units ("RSUs") that will vest in 3 installments as follows: 10,000 shall vest on each of January 1, 2025, January 1, 2026 and January 1, 2027. The RSUs convert into the Issuer's Common Stock on a one-for-one basis.
F2: Represents Restricted Stock Units ("RSUs") that will vest in quarterly installments of approximately 1,267 on April 1, 2024, July 1, 2024, October 1, 2024 and January 1, 2025. The RSUs convert into the Issuer's Common Stock on a one-for-one basis.
F3: These shares of common stock are held by a trust of which the reporting person is a trustee and beneficiary.